Search Within

Neha Sanat Korde

Formats
  1. Meeting Abstract (158)
  2. Journal Article (64)
  3. Research Letter (8)
  4. Correspondence (3)
  5. Review (3)
  6. Conference Paper (1)
Groups
  1. Center for Hematologic Malignancies (237)
  2. Department of Medicine (237)
  3. Hematologic Malignancies, Division of (237)
  4. Myeloma (237)
  5. Survivorship Research (237)
  6. Hematologic Malignancies Research (215)

More Groups

People
  1. Sham Mailankody (190)
  2. Alexander Lesokhin (172)
  3. Hani Hassoun (165)
  4. Malin Hultcrantz (154)
  5. Sergio Giralt (147)
  6. Heather Landau (145)

More People

Years
  1. 2025 (5)
  2. 2024 (44)
  3. 2023 (40)
  4. 2022 (34)
  5. 2021 (15)
  6. 2020 (14)

More Years

Publications
  1. Blood (91)
  2. Clinical Lymphoma, Myeloma and Leukemia (47)
  3. Journal of Clinical Oncology (17)
  4. Leukemia and Lymphoma (11)
  5. Blood Cancer Journal (8)
  6. Biology of Blood and Marrow Transplantation (7)

More Publications

Publishers
  1. American Society of Hematology (98)
  2. Elsevier Inc. (61)
  3. American Society of Clinical Oncology (17)
  4. Nature Publishing Group (14)
  5. Taylor & Francis Group (11)
  6. Ferrata Storti Foundation (7)

More Publishers

Results (237)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase 2 trial of colesevelam for lenalidomide-associated diarrhea
    Meeting Abstract

    Hultcrantz, M.; Hassoun, H.; Korde, N.; Mailankody, S.; Shekarkhand, T.; Burge, M.; Maclachlan, K. H.; Patel, D.; Shah, U. A.; Chung, D. J.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Stem cell mobilization characteristics for transplant eligible patients with newly diagnosed multiple myeloma (NDMM) treated with carfilzomib, lenalidomide, dexamethasone, and daratumumab (KRd-Dara)
    Meeting Abstract

    Bhutani, M.; Robinson, M.; Atrash, S.; Watts, N.; Paul, B.; Chhabra, S.; Korde, N.; Begic, X.; Foureau, D. M.; Chung, D. J.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Maintenance Therapy Cessation for Sustained MRD Negative Multiple Myeloma Patients
    Meeting Abstract

    Korde, N.; Diamond, B.; Burge, M.; Hassoun, H.; Landau, H.; Hultcrantz, M.; Mailankody, S.; Maclachlan, K. H.; Shah, U. A.; Derkach, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Carfilzomib, lenalidomide and dexamethasone (KRd) vs bortezomib, lenalidomide, and dexamethasone (VRd) as induction therapy in newly diagnosed high-risk multiple myeloma
    Meeting Abstract

    Tan, C.; Nemirovsky, D.; Derkach, A.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U. A.; Patel, D.; Maclachlan, K. H.; Lahoud, O. B.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Tracking the earliest genomic events in multiple myeloma life-history
    Meeting Abstract

    Cirrincione, A.; Ziccheddu, B.; Maclachlan, K. H.; Poos, A. M.; Chojnacka, M.; Diamond, B.; Boyle, E. M.; Blaney, P.; Gagler, D.; Zhang, Y.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Genomic determinants of resistance in newly diagnosed multiple myeloma treated with targeted-immunotherapy
    Meeting Abstract

    Maura, F.; Boyle, E.; Coffey, D.; Maclachlan, K. H.; Diamond, B.; Blaney, P.; Gagler, D.; Ziccheddu, B.; Ghamlouch, H.; Wang, Y.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Fc-mediated antibody effector function, inflammation resolution and oligoclonality on TCR rearrangements predict sustained MRD negativity in newly diagnosed multiple myeloma treated with immunotherapy regimens
    Meeting Abstract

    Boyle, E. M.; Maura, F.; Coffey, D.; Maclachlan, K. H.; Diamond, B.; Ghamlouch, H.; Gagler, D.; Blaney, P.; Ziccheddu, B.; Wang, Y.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Stem cell autograft minimal residual disease negativity improves outcomes after autotransplant for multiple myeloma
    Meeting Abstract

    Nishimura, N.; Brown, S.; Devlin, S. M.; Dahi, P. B.; Landau, H.; Lahoud, O. B.; Scordo, M.; Shah, G. L.; Hassoun, H.; Hultcrantz, M.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • A short course of daratumumab in patients with multiple myeloma and minimal residual disease after induction therapy
    Correspondence

    Nath, K.; Shekarkhand, T.; Salcedo, M.; Derkach, A.; Rueda, S.; Chansakul, A.; Hulcrantz, M.; Korde, N.; Shah, U. A.; Tan, C.; more...
    Leukemia and Lymphoma (2022)

    Fulltext@MSK | Save
  • Sustained minimal residual disease negativity in multiple myeloma is associated with stool butyrate and healthier plant-based diets
    Journal Article

    Shah, U. A.; Maclachlan, K. H.; Derkach, A.; Salcedo, M.; Barnett, K.; Caple, J.; Blaslov, J.; Tran, L.; Ciardiello, A.; Burge, M.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save